{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:28Z","timestamp":1788957388558,"version":"build-2803163510"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients on B-cell-depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or suffering from a more severe prognosis. Indeed, available data on pre-exposure prophylaxis with tixagevimab\/cilgavimab (Evusheld) in subjects with glomerular diseases (GDs) who received rituximab are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective study analysing the safety and efficacy of tixagevimab\/cilgavimab for pre-exposure prophylaxis in patients with GDs who received rituximab in the previous 12\u00a0months. The rates of symptomatic infections and hospitalizations were compared with those for patients with GD treated with rituximab who refused to receive tixagevimab\/cilgavimab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tixagevimab\/cilgavimab was administered to 22 patients (12 females, mean age 58.4\u00a0\u00b1\u00a019.6\u00a0years) with GD diagnoses including membranous nephropathy, lupus nephritis, anti-neutrophil cytoplasmic antibody\u2013associated vasculitis and focal segmental glomerulosclerosis. No patient treated with tixagevimab\/cilgavimab experienced symptomatic infection with SARS-CoV-2 during the follow-up (mean observation time of follow-up was 112\u00a0\u00b1\u00a023\u00a0days), while 11 of 28 controls (39.3%) reported a symptomatic infection (P\u00a0=\u00a0.0001), requiring hospitalization in 2 cases. Reported adverse events were mild, namely self-limiting headache [4], discomfort at the injection site [3], flu-like symptoms\/myalgia [3] and fever [1]. No serious adverse events (e.g. cardiac events, anaphylaxis) were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pre-exposure prophylaxis with tixagevimab\/cilgavimab seems safe and lowered the risk of symptomatic SARS-CoV-2 infection by \u224840% in vaccinated subjects with GD who received anti-CD20 therapy. Possible applications in the subset of patients who need immunosuppressive therapy, especially with rituximab, in a pandemic setting might be envisaged.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfad111","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:07:30Z","timestamp":1684202850000},"page":"1465-1468","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of pre-exposure prophylaxis with tixagevimab\/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"first","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia Antonietta","family":"Rilat","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Grazietta","family":"Foddai","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1941-2606","authenticated-orcid":false,"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacoma","family":"Cinnirella","sequence":"additional","affiliation":[{"name":"Pharmacy Department, S. Giovanni Bosco Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Crosasso","sequence":"additional","affiliation":[{"name":"Pharmacy Department, S. Giovanni Bosco Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Guidetti","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Barinotti","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Menegatti","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"2023083104280238100_bib1","doi-asserted-by":"crossref","first-page":"e2248664","DOI":"10.1001\/jamanetworkopen.2022.48664","article-title":"Analysis of rituximab use, time between rituximab and SARS-CoV-2 vaccination, and COVID-19 hospitalization or death in patients with multiple sclerosis","volume":"5","author":"Smith","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023083104280238100_bib2","first-page":"420","article-title":"B cell reconstitution is associated with COVID-19 booster vaccine responsiveness in patients previously seronegative treated with rituximab","volume":"50","author":"Schultz","year":"2023","journal-title":"J Rheumatol"},{"key":"2023083104280238100_bib3","doi-asserted-by":"crossref","first-page":"152149","DOI":"10.1016\/j.semarthrit.2022.152149","article-title":"Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)","volume":"58","author":"Singh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2023083104280238100_bib4","doi-asserted-by":"crossref","first-page":"108897","DOI":"10.1016\/j.clim.2021.108897","article-title":"Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: effect of timing and immunologic parameters","volume":"234","author":"Magliulo","year":"2022","journal-title":"Clin Immunol"},{"key":"2023083104280238100_bib5","doi-asserted-by":"crossref","first-page":"e2211497","DOI":"10.1001\/jamanetworkopen.2022.11497","article-title":"Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab","volume":"5","author":"Tolf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023083104280238100_bib6","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023083104280238100_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis ofCOVID-19","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"2023083104280238100_bib8","doi-asserted-by":"crossref","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023083104280238100_bib9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"2023083104280238100_bib10","article-title":"Inserimento del medicinale \u00abEvusheld\u00bb (associazione di anticorpi monoclonali tixagevimab e cilgavimab) nell'elenco dei medicinali ai sensi della legge 23 dicembre 1996, n. 648. (Determina n. DG\/344\/2022)","author":"Agenzia Italiana del Farmaco"},{"key":"2023083104280238100_bib11","article-title":"Covid-19: la mappa del Piemonte","author":"Regione Piemonte"},{"key":"2023083104280238100_bib12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023083104280238100_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ckj\/sfz127","article-title":"Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine a are out, rituximab is the new normal","volume":"12","author":"Rojas-Rivera","year":"2019","journal-title":"Clin Kidney J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad111\/50571828\/sfad111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/9\/1465\/51294901\/sfad111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/9\/1465\/51294901\/sfad111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:56:37Z","timestamp":1693457797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/9\/1465\/7163226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5,15]]},"published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad111","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,5,15]]}}}